We have observed
5 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 publication dated after
January 20, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
METHOD OF DRUG REPOSITIONING
N-CYCLOBUTYL-IMIDAZOPYRIDINE-METHYLAMINE AS TRPV1 ANTAGONISTS
PIPERAZINEDIONES AS OXYTOCIN RECEPTOR ANTAGONISTS
NAPHTHYRIDINE DERIVATIVES USEFUL AS ALPHA-V-BETA-6 INTEGRIN ANTAGONISTS
NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE